Merck to Develop New Bioprocessing Production Center in South Korea

Commercial Manufacturing Merck to Develop New Bioprocessing Production Center in South Korea

05.05.2023 Source: Press release Ahlam Rais Reading Time: 2 min

Related Vendors

AZO GmbH + Co. KG

Glatt Ingenieurtechnik GmbH

Maag Pump Systems AG

Under a MOU signed between Merck; the Ministry of Trade, Industry and Energy; and Daejeon City, all the parties will work together to develop a new Bioprocessing Center in South Korea. The project aims to support commercial manufacturing for its biotech and pharmaceutical customers in the Asia-Pacific region.

Pictured left to right: Chang Yang Lee, Minister of Trade, Industry & Energy, South Korea; Matthias Heinzel, Member of the Merck Executive Board and CEO Life Science; Jang Woo Lee, Mayor of Daejeon following the signing of the MOU.
(Source: Merck KGaA)

Daejeon City/South Korea – Merck has signed a non-binding Memorandum of Understanding (MoU) with the Ministry of Trade, Industry and Energy (Motie), and Daejeon City for a new Asia-Pacific Bioprocessing Center, aimed at supporting the region’s healthcare ecosystem. The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.

“South Korea is an emerging global leader in the biotech industry, and this Memorandum of Understanding demonstrates Merck’s commitment to the region by working closely with the government to better support our customers,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO, Life Science. “The proposed facility would play a vital role in fulfilling demand in the Asia-Pacific region while representing an important hub for further biopharma industry development in South Korea.”

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

“We expect this collaboration to serve as an opportunity for our pharmaceutical-bio sector to take a leap forward as the science and technology industry of South Korea,” said Chang Yang Lee, Minister of Trade, Industry & Energy. “Daejeon is the birthplace of the Korean biotech industry. Today, it’s where companies, big and small, are intensely focused on technological innovation and talent development to bring new and novel therapies to market,” said Jang Woo Lee, Mayor of Daejeon. “Together with Merck, this planned investment cooperation will help support Daejeon’s growth to become a world-class biotech hub.”

Merck also plans to work with the Daejeon Government to support biotech companies based in the Daedeok Research Complex located in Daejeon, as well as expand the bio-research cooperation with leading Korean universities.

(ID:49433687)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.